vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and EXPRO GROUP HOLDINGS N.V. (XPRO). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $367.6M, roughly 1.7× EXPRO GROUP HOLDINGS N.V.). On growth, EXPRO GROUP HOLDINGS N.V. posted the faster year-over-year revenue change (-6.0% vs -10.5%). Over the past eight quarters, QuidelOrtho Corp's revenue compounded faster (-6.6% CAGR vs -11.5%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Expro is an energy services provider headquartered in Houston, Texas, United States.
QDEL vs XPRO — Head-to-Head
Income Statement — Q1 FY2027 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $619.8M | $367.6M |
| Net Profit | $-91.8M | — |
| Gross Margin | — | 6.7% |
| Operating Margin | — | 0.0% |
| Net Margin | -14.8% | — |
| Revenue YoY | -10.5% | -6.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-1.35 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $619.8M | $367.6M | ||
| Q4 25 | — | $382.1M | ||
| Q3 25 | $699.9M | $411.4M | ||
| Q2 25 | $613.9M | $422.7M | ||
| Q1 25 | $692.8M | $390.9M | ||
| Q4 24 | $707.8M | $436.8M | ||
| Q3 24 | $727.1M | $422.8M | ||
| Q2 24 | $637.0M | $469.6M |
| Q1 26 | $-91.8M | — | ||
| Q4 25 | — | $5.8M | ||
| Q3 25 | $-733.0M | $14.0M | ||
| Q2 25 | $-255.4M | $18.0M | ||
| Q1 25 | $-12.7M | $13.9M | ||
| Q4 24 | $-178.4M | $23.0M | ||
| Q3 24 | $-19.9M | $16.3M | ||
| Q2 24 | $-147.7M | $15.3M |
| Q1 26 | — | 6.7% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 0.0% | ||
| Q4 25 | — | 3.1% | ||
| Q3 25 | -100.7% | 6.4% | ||
| Q2 25 | -29.4% | 7.7% | ||
| Q1 25 | 4.7% | 2.6% | ||
| Q4 24 | -14.2% | 7.3% | ||
| Q3 24 | 2.1% | 6.2% | ||
| Q2 24 | -18.4% | 5.9% |
| Q1 26 | -14.8% | — | ||
| Q4 25 | — | 1.5% | ||
| Q3 25 | -104.7% | 3.4% | ||
| Q2 25 | -41.6% | 4.3% | ||
| Q1 25 | -1.8% | 3.6% | ||
| Q4 24 | -25.2% | 5.3% | ||
| Q3 24 | -2.7% | 3.8% | ||
| Q2 24 | -23.2% | 3.3% |
| Q1 26 | $-1.35 | $0.05 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | $-10.78 | $0.12 | ||
| Q2 25 | $-3.77 | $0.16 | ||
| Q1 25 | $-0.19 | $0.12 | ||
| Q4 24 | $-2.54 | $0.20 | ||
| Q3 24 | $-0.30 | $0.14 | ||
| Q2 24 | $-2.20 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $140.4M | $170.7M |
| Total DebtLower is stronger | $2.5B | $79.1M |
| Stockholders' EquityBook value | $1.9B | $1.5B |
| Total Assets | $5.6B | $2.2B |
| Debt / EquityLower = less leverage | 1.33× | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $140.4M | $170.7M | ||
| Q4 25 | — | $196.1M | ||
| Q3 25 | $98.1M | $197.9M | ||
| Q2 25 | $151.7M | $206.8M | ||
| Q1 25 | $127.1M | $179.3M | ||
| Q4 24 | $98.3M | $183.0M | ||
| Q3 24 | $143.7M | $165.7M | ||
| Q2 24 | $107.0M | $133.5M |
| Q1 26 | $2.5B | $79.1M | ||
| Q4 25 | — | $79.1M | ||
| Q3 25 | $2.5B | $99.1M | ||
| Q2 25 | $2.1B | $121.1M | ||
| Q1 25 | $2.1B | $121.1M | ||
| Q4 24 | $2.1B | $121.1M | ||
| Q3 24 | $2.2B | $121.1M | ||
| Q2 24 | $2.2B | $121.1M |
| Q1 26 | $1.9B | $1.5B | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | $2.0B | $1.5B | ||
| Q2 25 | $2.8B | $1.5B | ||
| Q1 25 | $3.0B | $1.5B | ||
| Q4 24 | $3.0B | $1.5B | ||
| Q3 24 | $3.2B | $1.5B | ||
| Q2 24 | $3.2B | $1.5B |
| Q1 26 | $5.6B | $2.2B | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | $5.7B | $2.3B | ||
| Q2 25 | $6.4B | $2.3B | ||
| Q1 25 | $6.5B | $2.3B | ||
| Q4 24 | $6.4B | $2.3B | ||
| Q3 24 | $6.8B | $2.3B | ||
| Q2 24 | $6.7B | $2.3B |
| Q1 26 | 1.33× | 0.05× | ||
| Q4 25 | — | 0.05× | ||
| Q3 25 | 1.23× | 0.07× | ||
| Q2 25 | 0.74× | 0.08× | ||
| Q1 25 | 0.70× | 0.08× | ||
| Q4 24 | 0.72× | 0.08× | ||
| Q3 24 | 0.68× | 0.08× | ||
| Q2 24 | 0.70× | 0.08× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $25.3M |
| Free Cash FlowOCF − Capex | — | $23.2M |
| FCF MarginFCF / Revenue | — | 6.3% |
| Capex IntensityCapex / Revenue | — | 1.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $112.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $25.3M | ||
| Q4 25 | — | $57.1M | ||
| Q3 25 | $-45.5M | $63.2M | ||
| Q2 25 | $-46.8M | $48.4M | ||
| Q1 25 | $65.6M | $41.5M | ||
| Q4 24 | $63.7M | $97.4M | ||
| Q3 24 | $117.9M | $55.3M | ||
| Q2 24 | $-97.9M | $-13.2M |
| Q1 26 | — | $23.2M | ||
| Q4 25 | — | $23.2M | ||
| Q3 25 | $-94.7M | $39.0M | ||
| Q2 25 | $-84.3M | $27.2M | ||
| Q1 25 | $9.4M | $8.4M | ||
| Q4 24 | $16.5M | $53.0M | ||
| Q3 24 | $71.4M | $23.3M | ||
| Q2 24 | $-133.2M | $-49.5M |
| Q1 26 | — | 6.3% | ||
| Q4 25 | — | 6.1% | ||
| Q3 25 | -13.5% | 9.5% | ||
| Q2 25 | -13.7% | 6.4% | ||
| Q1 25 | 1.4% | 2.1% | ||
| Q4 24 | 2.3% | 12.1% | ||
| Q3 24 | 9.8% | 5.5% | ||
| Q2 24 | -20.9% | -10.5% |
| Q1 26 | — | 1.2% | ||
| Q4 25 | — | 8.9% | ||
| Q3 25 | 7.0% | 5.9% | ||
| Q2 25 | 6.1% | 5.0% | ||
| Q1 25 | 8.1% | 8.5% | ||
| Q4 24 | 6.7% | 10.2% | ||
| Q3 24 | 6.4% | 7.6% | ||
| Q2 24 | 5.5% | 7.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.89× | ||
| Q3 25 | — | 4.52× | ||
| Q2 25 | — | 2.69× | ||
| Q1 25 | — | 2.98× | ||
| Q4 24 | — | 4.23× | ||
| Q3 24 | — | 3.40× | ||
| Q2 24 | — | -0.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
XPRO
Segment breakdown not available.
